Eye Implant OZURDEX(R) Receives European Medicines Agency Authorisation For Non-Infectious Uveitis
Allergan announced today that the European Medicines Agency (EMA) has extended the Marketing Authorisation for OZURDEX® (dexamethasone 0.7mg intravitreal implant in applicator) in the 27 member states of the European Union to include the treatment of inflammation of the posterior segment of the eye presenting as non-infectious uveitis...